DIVISLAB

Divi's Laboratories share price & financials

Price
₹6,743
Market cap
₹2.2L Cr
Sector
Healthcare
Calls analysed
10
Latest concall · Q1 FY27 · call held 01 Aug 2026

Divi's Laboratories Limited Q1 FY27

Consolidated PAT ₹902 cr +66%Consolidated PBT ₹1,180 cr +61%Consolidated Total Income ₹3,144 cr +24%

What went well

  • Consolidated Total Income increased by 24.39% YoY to ₹3,144 crores.
  • Consolidated Profit After Tax (PAT) grew by 65.50% YoY to ₹902 crores.
  • Standalone revenue grew 10% in constant currency, with Custom Synthesis contributing 60% of revenue.

What to watch

  • Net forex loss of ₹7 crores in Q1 FY27, compared to a net gain of ₹39 crores in the prior year.
  • Elevated solvent costs and challenging global logistic conditions continue to impact operations.
Read the full call →

What Divi's Laboratories Limited does

Divi's Laboratories is an API-exclusive manufacturer that makes generic Active Pharmaceutical Ingredients, provides custom synthesis (contract manufacturing) of APIs and intermediates for global pharmaceutical innovators, and produces nutraceutical ingredients such as carotenoids. It does not market its own dosage forms or compete with its pharma customers, instead acting as a backward-integrated supplier that manufactures most key starting materials in-house to control quality and supply continuity. The company is expanding into newer areas such as peptide APIs (for GLP-1/GLP-2 therapies) and contrast media compounds alongside its core generics and custom synthesis business.

Segments

  • Generic APIs
  • Custom Synthesis
  • Nutraceuticals
Manufacturing facilities
3 (Unit 1 near Hyderabad, Unit 2 at Visakhapatnam, Unit 3 greenfield facility at Kakinada)
Manufacturing capacity
16,550 MT/KL
R&D centers
3 (Sanath Nagar Hyderabad, Choutuppal, Chippada Visakhapatnam)
Scientists across R&D and Process Development/Support Centers
~700
Products across therapeutic areas
~160
Country reach
100+ countries
Founded 1990Headquarters Hyderabad, IndiaEmployees 18,300 (FY 2024-25) Company website

Guidance record · Q1 FY27

what the last two calls moved 19 tracked 3 delivered 4 missed 12 open
  • Kakinada Phase 1 Commercial Start delivered said Q4 FY24 Promised: Around Q3 FY25 Q1 FY27: Already achieved.
  • Contrast Media Volume Growth missed said Q2 FY25 Promised: 20-30% YoY increase Q1 FY27: Promise remains missed. New updates focus on specific contract commercialization rather than overall volume growth targets.
  • CS Long-Term Agreement Commercialization delayed said Q4 FY25 Promised: Revenue impact by Q3 CY2026 / Q4 CY2026 or January 2027 Q1 FY27: Management confirms readiness for regulatory submissions but commercialization remains contingent on approvals, consistent with the previously delayed timeline of 2027.

All 19 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 26.2%, net profit up 60.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue2,302 2,297 2,536 2,357 2,660 +16%2,578 +12%2,793 +10%2,974 +26%
EBITDA729 747 881 743 895 +23%907 +21%943 +7%1,240 +67%
Net profit518 594 667 557 696 +34%598 +1%756 +13%891 +60%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +54.6% 1Y

₹6.0k₹7.0k₹8.0k₹9.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 12 Nov 2025Q3 FY26 — 11 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 31 Jul 2026

1Y: ₹6,031.5 on 10 Sept 2025 → ₹9,322. High ₹9,575 (8 Sept 2026), low ₹5,689.5 (26 Sept 2025).

How the price took the results

close before → close after

Q1 FY27
+6.6%
1 Aug
Q4 FY26
−1.9%
23 May
Q3 FY26
+3.4%
11 Feb
Q2 FY26
−0.3%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 10.4% a year over 3 years, FY23 to FY26. Operating margin widened to 33.6%.

Year endingFY23FY24FY25FY26
Revenue₹7.7k Cr₹7.7k Cr₹9.2k Cr₹10.4k Cr
Operating profit₹2.4k Cr₹2.2k Cr₹3.0k Cr₹3.5k Cr
Operating margin30.6%28.3%32.4%33.6%
Interest₹0 Cr₹3 Cr₹1 Cr₹23 Cr
Depreciation₹345 Cr₹376 Cr₹401 Cr₹461 Cr
Net profit₹1.8k Cr₹1.6k Cr₹2.2k Cr₹2.6k Cr
Net margin23.6%20.6%24.0%25.1%
Cash from operations₹2.4k Cr₹1.3k Cr₹1.6k Cr₹2.7k Cr
Free cash flow₹2.0k Cr₹264 Cr₹213 Cr₹195 Cr
ROCE19.0%16.0%21.0%22.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹53 Cr₹53 Cr₹53 Cr₹53 Cr₹53 Cr₹53 Cr
Reserves₹9.2k Cr₹11.6k Cr₹12.7k Cr₹13.4k Cr₹15.4k Cr₹16.7k Cr
Borrowings₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹90 Cr₹0 Cr
Other liabilities₹1.5k Cr₹1.6k Cr₹1.6k Cr₹1.9k Cr₹2.6k Cr₹3.2k Cr
Total liabilities₹10.7k Cr₹13.3k Cr₹14.4k Cr₹15.4k Cr₹18.2k Cr₹20.0k Cr
Fixed assets₹3.7k Cr₹4.3k Cr₹4.7k Cr₹4.7k Cr₹5.7k Cr₹6.5k Cr
Capital work in progress₹711 Cr₹470 Cr₹212 Cr₹778 Cr₹2.0k Cr₹2.1k Cr
Investments₹7 Cr₹79 Cr₹84 Cr₹89 Cr₹67 Cr₹76 Cr
Other assets₹6.3k Cr₹8.4k Cr₹9.3k Cr₹9.8k Cr₹10.4k Cr₹11.2k Cr
Total assets₹10.7k Cr₹13.3k Cr₹14.4k Cr₹15.4k Cr₹18.2k Cr₹20.0k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −0.79 pp while FIIs added +0.45 pp. The shareholder count shrank 13% to 2,26,324.

Promoters
51.9%
FIIs
20.2%
DIIs
19.3%
Government
0.1%
Public
8.5%

Since Jun 2025

  • Public −0.79 pp
  • FIIs +0.45 pp
  • DIIs +0.33 pp

How it drifted, 12 quarters

Over this window FIIs went from 14.6% to 20.2% — +5.6 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 51.9%, FIIs 14.6%, DIIs 21.6%, Government 0.1%, Public 11.7%.Dec '23: Promoters 51.9%, FIIs 14.8%, DIIs 21.8%, Government 0.1%, Public 11.3%.Mar '24: Promoters 51.9%, FIIs 14.7%, DIIs 22.1%, Government 0.1%, Public 11.2%.Jun '24: Promoters 51.9%, FIIs 16.2%, DIIs 21.7%, Government 0.1%, Public 10.2%.Sep '24: Promoters 51.9%, FIIs 17.3%, DIIs 21.0%, Government 0.1%, Public 9.8%.Dec '24: Promoters 51.9%, FIIs 18.0%, DIIs 20.4%, Government 0.1%, Public 9.6%.Mar '25: Promoters 51.9%, FIIs 18.0%, DIIs 20.6%, Government 0.1%, Public 9.4%.Jun '25: Promoters 51.9%, FIIs 19.7%, DIIs 19.0%, Government 0.1%, Public 9.3%.Sep '25: Promoters 51.9%, FIIs 19.4%, DIIs 19.7%, Government 0.1%, Public 9.0%.Dec '25: Promoters 51.9%, FIIs 20.1%, DIIs 19.2%, Government 0.1%, Public 8.8%.Mar '26: Promoters 51.9%, FIIs 20.3%, DIIs 19.1%, Government 0.1%, Public 8.6%.Jun '26: Promoters 51.9%, FIIs 20.2%, DIIs 19.3%, Government 0.1%, Public 8.5%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 4 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Divi's Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Satchandra Kiran Divi 20.34%unchanged
Nilima Prasad Divi 20.34%unchanged
Swarna Latha Divi 5.27%unchanged
SBI Mutual Fund Mutual fund3.90%−0.31 pp
Government Of Singapore - E Sovereign3.64%−0.25 pp
Divi'S Biotech Private Limited 3.01%unchanged
Murali Krishna Prasad Divi 2.85%unchanged
Life Insurance Corporation Of India Insurer2.53%−0.26 pp
HDFC Mutual Fund Mutual fund2.07%+0.07 pp
Axis Mutual Fund Trustee Ltd. Mutual fund1.38%unchanged
Nippon Life India Trustee Ltd. Mutual fund1.29%−0.05 pp
Government Pension Fund Global Sovereign1.23%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in DIVISLAB

Filings to Aug 2026

1 new, 18 added, 6 trimmed, 0 sold out — net −3.10 L shares (−1.6%).

Held by funds
₹16.9k Cr
58 schemes
Biggest holder
SBI Large Cap Fund
₹1.9k Cr · 3.5% of that fund
SchemeHoldingLast month
SBI Large Cap Fund SBI Mutual Fund₹1.9k Crheld
SBI Aggressive Hybrid Fund SBI Mutual Fund₹1.8k Cr−4.00 L
HDFC Flexi Cap Fund HDFC Mutual Fund₹1.5k Cr+0.93 L
SBI Focused Fund SBI Mutual Fund₹1.5k Crheld
Nippon India Large Cap Fund Nippon India Mutual Fund₹815 Crheld
SBI MultiCap Fund SBI Mutual Fund₹805 Crheld
SBI Large and Midcap Fund SBI Mutual Fund₹786 Crheld
HDFC Balanced Advantage Fund HDFC Mutual Fund₹716 Crheld

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

18 added, 6 trimmed — net −3.10 L shares (−1.6%)

Funds are sitting on
+36%
vs est. average cost
Held by funds
₹16.9k Cr
58 schemes · ≈ 5.7% of the company
Biggest holder
SBI Large Cap Fund
₹1.9k Cr · 3.5% of that fund
Longest holder
Nippon India Large Cap Fund
14y · since Sep '12

Shares held by these funds −16%

Aug '23 1.91 cr shares Jul '26

What the price assumes

Growth trap

To justify its price of ₹9322, this stock must grow earnings at 42% every year for 7 years. Our analysis caps realistic growth at ~13%. At that growth it is worth ₹2159 — downside of 77%.

Growth the price implies
42.3% a year
for 7 years, fading to 4%
It has actually compounded at
12.7% a year
net profit, FY23–FY26 · EPS 12.7%
The gap
0.3 pp
-77% downside if it only repeats history
Price today ₹9,322 Value at the reference growth ₹2,159.45

Change the assumptions yourself →

All earnings calls (10)

Read the Q1 FY27 call →

Learn to analyse Divi's Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.